UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ Form 10-Q _______________________________________________________________________ (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 _______ ...

iRhythm Technologies, Inc. (NASDAQ:IRTC) Q3 2019 Earnings Conference Call November 5, 2019 4:30 PM ET Company Participants Lynn Lewis – Investor Relations-Gilmartin Group Kevin King – President and Chief Executive Officer Matthew Garrett – Chief Financial Officer Conference Call Participants Allen Gong – JPMorgan Jason Mills – Canaccord Genuity Lynn Lewis Thank you, this is Lynn Lewis from Gilmartin Group. Thank you all for participating in today's call to iRhythm’s Q3 2019 conference call. Joining me are K ...

Market Opportunity and Expansion - The Total Addressable Market (TAM) for iRhythm's Zio service is over $2 billion[9] - The symptomatic initial diagnosis market is estimated at 4.5 million patients per year[9, 10] - Zio AT adoption is experiencing early benefits, potentially capturing 14% of the high-acuity segment, while Zio XT captures 10%[19] - A study showed a 3x increase in stroke risk in paroxysmal AF patients with a True AF burden greater than 11% when measured by Zio[21] - mSToPS study showed a 9x increase in detection of AF with Zio at 4 months and a 3x increase at 1 year[23] Technology and Clinical Advantages - iRhythm's Zio service is clinically proven and highly differentiated, utilizing a patented wearable biosensor and proprietary data analytics[8] - iRhythm's deep neural network (DNN) exceeded cardiologist ECG interpretation for all 12 rhythm classes[27] - The DNN optimization is built on a proprietary database of over 10 years and >400 million hours of curated data[27] - Incidence of First Critical Arrhythmias Detected Beyond 7-Days: Paroxysmal AF 13%, AV block 16%, Pause 18%, Ventricular tachycardia 22%[16] Business Performance - The company's revenue is estimated to be between $212 million and $216 million in 2019[36] - The company's gross margin has increased from 51% in 2014 to an estimated 75.5-76.5% in 2019[34, 35]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 20-8149544 (State or Other Jurisdiction of Incorporation or Organ ...

iRhythm Technologies, Inc. (NASDAQ:IRTC) Q2 2019 Earnings Conference Call July 31, 2019 4:30 PM ET Company Participants Lynn Lewis – Investor Relations-Gilmartin Group Kevin King – Chief Executive Officer Matthew Garrett – Chief Financial Officer Conference Call Participants David Lewis – Morgan Stanley Operator Good afternoon, my name is Sylvia and I will be your conference operator today. At this time I’d like to welcome everyone to the iRhythm Technologies Second Quarter 2019 Conference Call. [Operator ...

iRhythm 1 ©2019 iRhythm Technologies, Inc. Content is Confidential and Proprietary. Investor Presentation June 2019 Safe Harbor Certain data in this presentation was obtained from various external sources, and neither "iRhythm" or the "Company" nor its affiliates or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy of that data or undertakes to update such data ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37918 iRhythm Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 20-8149544 (State or Other Jurisdiction of Incorporation or Orga ...

iRhythm Technologies, Inc. (NASDAQ:IRTC) Q1 2019 Earnings Conference Call May 7, 2019 4:30 PM ET Company Participants Lynn Lewis – Investor Relations Kevin King – Chief Executive Officer Matt Garrett – Chief Financial Officer Conference Call Participants David Lewis – Morgan Stanley Robbie Marcus – J.P. Morgan Cecilia Furlong – Canaccord Genuity Operator Good afternoon, ladies and gentlemen, and welcome to the iRhythm Technologies, Inc. Q1 2019 Earnings Conference Call. At this time, all participants are in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37918 iRhythm Technologies, Inc. (Exact name of Registrant as specified in its Charter) Delaware 20-8149544 (State or other jurisdict ...